UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment

Antimicrobial agents and chemotherapy, 2014-11, Vol.58 (11), p.6471-6476

2014

Volltextzugriff (PDF)

A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus

Journal of viral hepatitis, 2015-12, Vol.22 (12), p.1011-1019

2015

Volltextzugriff (PDF)

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study

Journal of viral hepatitis, 2016-08, Vol.23 (8), p.614-622

2016

Volltextzugriff (PDF)

An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment

Journal of clinical pharmacy and therapeutics, 2013-12, Vol.38 (6), p.518-523

2013

Volltextzugriff (PDF)

THU0139 Pharmacokinetics of fostamatinib in patients with impaired hepatic function: A phase I study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.202-202

2013

Volltextzugriff (PDF)

THU0138 Pharmacokinetics of fostamatinib in patients with impaired renal function: A phase I study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.202-202

2013

Volltextzugriff (PDF)

P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment

Journal of hepatology, 2015-04, Vol.62, p.S590-S591

2015

Volltextzugriff (PDF)

Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease

Journal of clinical pharmacology, 2005-02, Vol.45 (2), p.185-192

2005

Volltextzugriff (PDF)

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients

Diabetes care, 1999-05, Vol.22 (5), p.789-794

1999

Volltextzugriff (PDF)

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Journal of human hypertension, 2003-06, Vol.17 (6), p.425-432

2003

Volltextzugriff (PDF)

The Effect of Renal or Hepatic Impairment on the Pharmacokinetics of GS-9857, a Pan-Genotypic HCV NS3/4A Protease Inhibitor

Journal of hepatology, 2016, Vol.64 (2), p.S613-S613

2016

Volltextzugriff (PDF)

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2012-05, Vol.35 (10), p.1209-1220

2012

Volltextzugriff (PDF)

Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

The journal of clinical hypertension (Greenwich, Conn.), 2001-09, Vol.3 (5), p.283-318

2001

Volltextzugriff (PDF)

P0901 : The pan-genotypic NS3/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study

Journal of hepatology, 2015-04, Vol.62, p.S682-S682

2015

Volltextzugriff (PDF)

Pharmacokinetics of repaglinide in subjects with renal impairment

Clinical pharmacology and therapeutics, 2000-01, Vol.67 (1), p.7-15

2000

Volltextzugriff (PDF)

1211 NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HCV GT-1 PATIENTS

Journal of hepatology, 2012-04, Vol.56, p.S480-S481

2012

Volltextzugriff (PDF)

P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT

Journal of hepatology, 2014-04, Vol.60 (1), p.S317-S317

2014

Volltextzugriff (PDF)

593 Pharmacokinetics (PK) and Pharmacodynamics (PD) of Liposomal Mifamurtide (L-MTP-PE) in Adult Volunteers with Mild and Moderate Hepatic Impairment (HI)

European journal of cancer (1990), 2012-11, Vol.48, p.182-182

2012

Volltextzugriff (PDF)

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

Journal of clinical pharmacology, 2008-06, Vol.48 (6), p.726-733

2008

Volltextzugriff (PDF)

847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS

Journal of hepatology, 2013-04, Vol.58, p.S347-S347

2013

Volltextzugriff (PDF)

1190 STUDY OF ABT-267 2-DAY MONOTHERAPY FOLLOWED BY 12-WEEK COMBINATION THERAPY IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION

Journal of hepatology, 2013-04, Vol.58, p.S484-S484

2013

Volltextzugriff (PDF)

1206 PHARMACODYNAMICS OF ORAL TLR-7 AGONIST GS-9620 IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C

Journal of hepatology, 2013-04, Vol.58, p.S490-S490

2013

Volltextzugriff (PDF)

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

Journal of hepatology, 2012-04, Vol.56, p.S469-S470

2012

Volltextzugriff (PDF)

7055 POSTER A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment

European journal of cancer (1990), 2011, Vol.47, p.S501-S501

2011

Volltextzugriff (PDF)

7057 POSTER A Phase 1 Single Dose Open-label Reduced/staged Pharmacokinetic (PK) and Safety Study of Abiraterone Acetate (AA) in Men With Impaired Renal Function

European journal of cancer (1990), 2011, Vol.47, p.S502-S502

2011

Volltextzugriff (PDF)

1 – 25 von 888

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(518)
Mit Volltextzugriff
(634)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(887)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(306)
MEDLINE
(283)
Journals@Ovid Full Text
(253)
Ingenta
(168)
Wiley-Blackwell Journals
(132)
JSTOR
(126)
Access via Business Source (EBSCOhost)
(121)
Publisher or Other Site
(108)
Wiley Online Library Full Collection 2018
(101)
Elsevier ScienceDirect Journals Complete
(86)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(72)
IngentaConnect Journals
(67)
Nexis Uni
(58)
Ebook Central Perpetual and DDA
(42)
eBooks on EBSCOhost
(42)
De Gruyter eBooks
(41)
Oxford University Press Books All Titles
(41)
Springer journals
(39)
Oxford Journals
(31)
Oxford Journals 2020 Medicine
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment

A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study

An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment

THU0139 Pharmacokinetics of fostamatinib in patients with impaired hepatic function: A phase I study

THU0138 Pharmacokinetics of fostamatinib in patients with impaired renal function: A phase I study

P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment

Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

The Effect of Renal or Hepatic Impairment on the Pharmacokinetics of GS-9857, a Pan-Genotypic HCV NS3/4A Protease Inhibitor

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C

Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

P0901 : The pan-genotypic NS3/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study

Pharmacokinetics of repaglinide in subjects with renal impairment

1211 NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HCV GT-1 PATIENTS

P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT

593 Pharmacokinetics (PK) and Pharmacodynamics (PD) of Liposomal Mifamurtide (L-MTP-PE) in Adult Volunteers with Mild and Moderate Hepatic Impairment (HI)

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS

1190 STUDY OF ABT-267 2-DAY MONOTHERAPY FOLLOWED BY 12-WEEK COMBINATION THERAPY IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION

1206 PHARMACODYNAMICS OF ORAL TLR-7 AGONIST GS-9620 IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

7055 POSTER A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment

7057 POSTER A Phase 1 Single Dose Open-label Reduced/staged Pharmacokinetic (PK) and Safety Study of Abiraterone Acetate (AA) in Men With Impaired Renal Function

Suchergebnisse filtern